CEO David Main (Notch)
'Industrializing the production of cells': Another iPSC player joins the quest for off-the-shelf cell therapies
Scientists have been after the “Holy Grail” of cell therapy — an off-the-shelf product — for years. Notch Therapeutics is now joining the quest with a tech …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.